688767.SH
博拓生物
SSE · Healthcare · Biotechnology · CN
CNY 35.16
−13.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 449.5M | 448.0M | 559.4M | 442.1M | 1.9B |
| Cost of Revenue | 241.4M | 241.8M | 263.8M | 219.6M | 884.8M |
| Gross Profit | 208.2M | 206.2M | 295.6M | 222.5M | 1.0B |
| Operating Expenses | |||||
| R&D Expense | 90.0M | 83.5M | 63.6M | 80.5M | 108.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 60.1M | 59.3M | 55.0M | 51.3M | 57.6M |
| Selling & Marketing Expense | 36.2M | 38.3M | 30.9M | 27.9M | 28.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 196.4M | 173.9M | 97.6M | 79.4M | 65.9M |
| Cost and Expenses | 437.7M | 415.7M | 361.4M | 299.0M | 950.7M |
| Operating Income (EBIT) | 26.7M | 50.5M | 193.4M | 116.8M | 914.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 25.8M | 49.7M | 194.9M | 115.9M | 901.9M |
| Income Tax Expense | (3.2M) | 2.6M | 28.1M | 10.6M | 128.3M |
| Bottom Line | |||||
| Net Income | 30.3M | 49.3M | 169.5M | 106.6M | 773.6M |
| Earnings from Cont. Ops | 28.9M | 47.1M | 166.8M | 105.3M | 773.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 30.3M | 49.3M | 169.5M | 106.6M | 773.6M |
| Per Share | |||||
| Basic EPS | CN¥0.20 | CN¥0.34 | CN¥1.15 | CN¥1.00 | CN¥7.25 |
| Diluted EPS | CN¥0.20 | CN¥0.34 | CN¥1.15 | CN¥1.00 | CN¥7.25 |
| Revenue Per Share | CN¥3.08 | CN¥3.09 | CN¥3.80 | CN¥4.15 | CN¥17.82 |
| Shares | |||||
| Basic Shares Outstanding | 145.8M | 144.9M | 147.4M | 106.6M | 106.7M |
| Diluted Shares Outstanding | 145.8M | 144.9M | 147.4M | 106.6M | 106.7M |
| Profitability Metrics | |||||
| EBITDA | — | 74.8M | 214.8M | 141.6M | 934.3M |
| D&A | — | 24.3M | 21.4M | 24.8M | 20.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026